Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Unicycive Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
UNCY
Nasdaq
2830
unicycive.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Unicycive Therapeutics, Inc.
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
- Jan 28th, 2025 12:00 pm
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation
- Jan 28th, 2025 11:58 am
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
- Jan 7th, 2025 12:00 pm
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
- Dec 17th, 2024 12:00 pm
Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
- Nov 28th, 2024 11:57 am
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
- Nov 21st, 2024 12:00 pm
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
- Nov 13th, 2024 12:15 pm
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
- Nov 11th, 2024 12:00 pm
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
- Oct 28th, 2024 11:03 am
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
- Oct 16th, 2024 8:35 pm
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
- Oct 16th, 2024 3:43 pm
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
- Oct 14th, 2024 11:03 am
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
- Oct 9th, 2024 11:03 am
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
- Sep 24th, 2024 11:03 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
- Sep 20th, 2024 12:35 pm
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
- Sep 16th, 2024 4:07 pm
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
- Sep 16th, 2024 11:03 am
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 5th, 2024 11:03 am
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
- Sep 3rd, 2024 11:03 am
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
- Aug 26th, 2024 11:03 am
Scroll